Piper Jaffray, which downgraded shares of MedAssets, Inc. MDAS – and lowered its PT from $21 to $15 – is providing some color on its 4Q results.
“MDAS Q4 earnings missed on the top and bottom line, they guided below our street-low 2011 estimates, RCM backlog showed no growth,” Piper Jaffray writes. “Separately, Medtronic announced it is cancelling its GPO contracts with both Novation and Premier, adding uncertainty to the long-term sustainability of the current GPO model. We also believe there is renewal risk in certain provider contracts.”
MedAssets, Inc closed Thursday at $21.32.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in